Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy
Investigators also assessed safety outcomes, focusing primarily on serious adverse events since this outcome was available in all trials using common serious adverse event criteria for reporting
The brand uses a patented blend of prebiotic fibers and feeds the good gut microbes, regulating GLP-1 production and signaling the brain to stop eating
Never discontinue semaglutide abruptly without medical guidance, as this may affect your diabetes control or weight management progress
Compounded tirzepatide is considerably less expensive than brand-name Mounjaro, but still represents a significant monthly investment
Specificity This assay has high sensitivity for detection of Glucagon Like Peptide 1 (GLP1)
